300 related articles for article (PubMed ID: 30919155)
1. Cutaneous toxicities of antineoplastic agents: data from a large cohort of Greek patients.
Nikolaou V; Voudouri D; Tsironis G; Charpidou A; Stamoulis G; Triantafyllopoulou I; Panoutsopoulou I; Xidakis E; Bamias A; Samantas E; Aravantinos G; Gogas H; Rigopoulos D; Syrigos K; Stratigos A
Support Care Cancer; 2019 Dec; 27(12):4535-4542. PubMed ID: 30919155
[TBL] [Abstract][Full Text] [Related]
2. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
Yalici-Armagan B; Ayanoglu BT; Demirdag HG
Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
[No Abstract] [Full Text] [Related]
3. Clinical associations and classification of immune checkpoint inhibitor-induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients.
Nikolaou VA; Apalla Z; Carrera C; Fattore D; Sollena P; Riganti J; Segura S; Freites-Martinez A; Lallas K; Romano MC; Oikonomou C; Starace M; Dimopoulos MA; Kyrgidis A; Lazaridou E; Giavedoni P; Annunziata MC; Peris K; Echeverría M; Lopez-Tujillo E; Syrigos K; Papageorgiou C; Podlipnik S; Fabbrocini G; Torre AC; Kemanetzi C; Villa-Crespo L; Lallas A; Stratigos AJ; Sibaud V
Br J Dermatol; 2022 Dec; 187(6):962-969. PubMed ID: 35861701
[TBL] [Abstract][Full Text] [Related]
4. Dermatologic Reactions to Immune Checkpoint Inhibitors : Skin Toxicities and Immunotherapy.
Sibaud V
Am J Clin Dermatol; 2018 Jun; 19(3):345-361. PubMed ID: 29256113
[TBL] [Abstract][Full Text] [Related]
5. Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review.
Yuan C; Wang B
J Cosmet Dermatol; 2023 Aug; 22(8):2150-2157. PubMed ID: 36924348
[TBL] [Abstract][Full Text] [Related]
6. Managing skin toxicities related to panitumumab.
Bergman H; Walton T; Del Bel R; Seki JT; Rafii A; Xu W; Koren G; Shear N; Krzyzanowska MK; Howell D; Liu G
J Am Acad Dermatol; 2014 Oct; 71(4):754-9. PubMed ID: 25085331
[TBL] [Abstract][Full Text] [Related]
7. Skin Manifestations of Targeted Antineoplastic Therapy.
Sanmartín O
Curr Probl Dermatol; 2018; 53():93-104. PubMed ID: 29131041
[TBL] [Abstract][Full Text] [Related]
8. Inflammatory eruptions associated with immune checkpoint inhibitor therapy: A single-institution retrospective analysis with stratification of reactions by toxicity and implications for management.
Coleman E; Ko C; Dai F; Tomayko MM; Kluger H; Leventhal JS
J Am Acad Dermatol; 2019 Apr; 80(4):990-997. PubMed ID: 30399387
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Kiyohara Y; Yamazaki N; Kishi A
J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy.
Keiser MF; Patel AB; Altan M
Clin Lung Cancer; 2021 May; 22(3):195-200.e1. PubMed ID: 33637416
[TBL] [Abstract][Full Text] [Related]
12. Acneiform eruptions: a common cutaneous toxicity of the MEK inhibitor trametinib.
Anforth R; Liu M; Nguyen B; Uribe P; Kefford R; Clements A; Long GV; Fernandez-Peñas P
Australas J Dermatol; 2014 Nov; 55(4):250-4. PubMed ID: 24313958
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous adverse reactions linked to targeted anticancer therapies bortezomib and lenalidomide for multiple myeloma: new drugs, old side effects.
Patrizi A; Venturi M; Dika E; Maibach H; Tacchetti P; Brandi G
Cutan Ocul Toxicol; 2014 Mar; 33(1):1-6. PubMed ID: 23638756
[TBL] [Abstract][Full Text] [Related]
14. Will cetuximab-induced follicular rash get worse with moisturizers containing liquid paraffinum?
Manganoni AM; Pavoni L; Calzavara-Pinton P
Jpn J Clin Oncol; 2014 Jun; 44(6):607-8. PubMed ID: 24755543
[No Abstract] [Full Text] [Related]
15. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: A United States population-level analysis.
Wongvibulsin S; Pahalyants V; Kalinich M; Murphy W; Yu KH; Wang F; Chen ST; Reynolds K; Kwatra SG; Semenov YR
J Am Acad Dermatol; 2022 Mar; 86(3):563-572. PubMed ID: 33819538
[TBL] [Abstract][Full Text] [Related]
16. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
17. "I Lost My Image, the Image Others Know Me By": Findings From a Hermeneutic Phenomenological Study of Patients Living With Treatment-Induced Cutaneous Toxicities.
Charalambous A; Charalambous M
Res Nurs Health; 2016 Jun; 39(3):187-96. PubMed ID: 27080722
[TBL] [Abstract][Full Text] [Related]
18. Cutaneous Adverse Reactions of Anticancer Agents.
Kaul S; Kaffenberger BH; Choi JN; Kwatra SG
Dermatol Clin; 2019 Oct; 37(4):555-568. PubMed ID: 31466595
[TBL] [Abstract][Full Text] [Related]
19. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
Lacouture M; Sibaud V
Am J Clin Dermatol; 2018 Nov; 19(Suppl 1):31-39. PubMed ID: 30374901
[TBL] [Abstract][Full Text] [Related]
20. Twelve cases of acneiform eruptions while on anti-CTLA4 therapy.
Welborn M; Kubicki SL; Garg N; Patel AB
Support Care Cancer; 2020 Jun; 28(6):2499-2502. PubMed ID: 32147760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
